Original Article
Copyright ©2014 Baishideng Publishing Group Inc.
World J Transplant. Sep 24, 2014; 4(3): 188-195
Published online Sep 24, 2014. doi: 10.5500/wjt.v4.i3.188
Figure 1
Figure 1 Trends in the use of induction agents. A: Steroid free group; B: Steroid-maintenance group; r-ATG: Rabbit antithymocyte globulin; IL-2B: Interleukin-2 receptor blocker.
Figure 2
Figure 2 Adjusted over-all graft (A, B and C), death-censored graft (D, E and F) and patient (G, H and I) survivals for early steroid withdrawal vs chronic steroid maintenance groups. A: Adjusted over-all graft rabbit antithymocyte globulin (r-ATG); B: Adjusted over-all graft alemtuzumab; C: Adjusted over-all graft interleukin-2 receptor blocker (IL-2B); D: Death-censored graft r-ATG; E: Death-censored graft alemtuzumab; F: Death-censored graft IL-2B; G: Patient r-ATG; H: Patient alemtuzumab; I: Patient IL-2B.
Figure 3
Figure 3 Adjusted over-all graft (A and B), death-censored graft (C and D) and patient (E and F) survivals in rabbit antithymocyte globulin induced patients. A: Adjusted over-all graft low-risk; B: Adjusted over-all graft high-risk; C: Death-censored graft low-risk; D: Death-censored graft high-risk; E: Patient low-risk; F: Patient high-risk.